The Problem With the Standard Narrative

For decades, depression has been explained almost entirely through the lens of serotonin. The story goes: serotonin is low, SSRIs raise it, mood improves. Clean and simple.

But that model does not account for why so many people with depression feel worse on SSRIs, why stimulant-type antidepressants cause agitation rather than relief, or why someone can have normal serotonin levels and still experience profound, treatment-resistant depression.

The data from hundreds of genetic reports paints a different picture. Depression is rarely one pathway failing. It is multiple systems under pressure simultaneously, and your genes are telling you exactly which ones.

Six Genetic Mechanisms Driving Depression

These are the patterns appearing most consistently across clients who report depression, have been diagnosed with depression, or are actively treating it with medication.

1. COMT Variants and the Accumulation Problem

The COMT gene (catechol-O-methyltransferase) encodes an enzyme that breaks down dopamine, norepinephrine, and epinephrine. The rs4680 variant, commonly known as Val158Met, is the most studied. In its slow form (AA genotype), COMT enzyme activity drops significantly. Catecholamines accumulate rather than clearing efficiently.

This is where the standard depression model breaks down entirely. Most of these clients do not have low dopamine. They have elevated dopamine that cannot clear. The result is nervous system overload, not depletion. Anxiety, emotional volatility, brain fog, and fatigue are the symptoms, not low mood from low neurotransmitters.

When a clinician adds an SSRI or an SNRI that further raises catecholamines, the system gets more congested, not less. Many clients report feeling worse, more activated, more anxious. Their genetics predicted this outcome.

2. Neuroinflammation: The Cytokine Theory of Depression

The inflammatory model of depression has growing research support, and the genetic data is consistent with it. IL-6, TNF-alpha, IL-1B, and CRP variants appear throughout these reports, and they are not coincidental findings.

Chronically elevated pro-inflammatory cytokines do several things that directly produce depression symptoms. They reduce tryptophan availability by shunting it toward the kynurenine pathway rather than serotonin synthesis. They increase oxidative stress in the prefrontal cortex. They disrupt the hypothalamic-pituitary-adrenal axis, altering cortisol patterns and stress response. They suppress BDNF expression.

The result is a nervous system that is perpetually bracing for threat, fatigued, and unable to recover. What presents clinically as depression is, at the biochemical level, a sustained neuroimmune stress response.

3. BDNF Val66Met and Reduced Neuroplasticity

Brain-derived neurotrophic factor is the brain's primary growth and repair signal. The BDNF Val66Met variant (rs6265) reduces activity-dependent BDNF secretion, meaning the brain produces less of this repair signal in response to learning, stress, or new experience.

Low BDNF does not cause acute mood crashes. It creates rigidity. The brain has less capacity to adapt, recover from stress, form new neural connections, and shift out of ruminative states. Depression in these individuals tends to be slow to lift even with intervention, because the neuroplasticity required for emotional recovery is genetically constrained.

4. Mitochondrial Insufficiency as a Mood Driver

SOD2, UCP2, NDUFS7, PPARGC1A, and TFAM variants appear consistently in these reports. These genes influence mitochondrial antioxidant defense, electron transport chain efficiency, and mitochondrial biogenesis. When several of these are compromised simultaneously, mitochondrial output drops and reactive oxygen species accumulate.

The brain is the most metabolically expensive organ in the body. It consumes approximately 20% of total energy despite comprising only 2% of body weight. When mitochondria underperform, the brain is the first system to show it. Fatigue, brain fog, difficulty sustaining attention, and emotional flatness are the downstream consequences of inadequate ATP production in neural tissue.

5. Methylation and Neurotransmitter Recycling

MTHFR C677T and A1298C variants are among the most commonly identified in depression-associated reports. These reduce the efficiency of converting dietary folate into active methylfolate, which is required for neurotransmitter synthesis, homocysteine clearance, and DNA repair. MTRR and MTR variants further compromise B12 regeneration.

Impaired methylation creates a shortage of the methyl groups needed to synthesize serotonin, dopamine, and norepinephrine precursors. It also allows homocysteine to accumulate, which is independently neurotoxic and pro-inflammatory. This is a biochemical environment that makes mood stability significantly harder to maintain.

6. Serotonin Pathway Variants

Beyond transport, serotonin signaling is shaped by several gene families. HTR2A and HTR1A variants influence receptor density and sensitivity. TPH2 variants affect tryptophan hydroxylase, the rate-limiting enzyme for serotonin synthesis. Together, these create structural inefficiencies in the serotonin system that are not about absolute serotonin levels, but about how effectively the signal is generated, received, and sustained.

Why Standard Treatments Miss the Mark Genetically

SSRIs block serotonin reuptake, increasing synaptic serotonin. For clients with slow serotonin transport and adequate COMT activity, this can be genuinely helpful. For clients with slow COMT and already elevated catecholamines, adding more neurotransmitter load to an already congested system produces agitation, emotional blunting, or paradoxical worsening.

SNRIs raise both serotonin and norepinephrine. For a slow COMT carrier, this means even more catecholamine load that cannot clear efficiently. The genetic data explains why these medications produce such variable outcomes, and why one person can thrive on a particular antidepressant while another person with similar symptoms deteriorates on the same drug.

This is not an argument against medication. It is an argument for precision. The genetics provide a map. The map shows whether the system needs more signal or better clearance, more synthesis or better recycling, more production or less oxidative noise.

Vitamin C and Depression: The Physiology Behind the Evidence

How Vitamin C Directly Affects Neurotransmitter Function

Vitamin C is a required cofactor for two enzymes that are central to neurotransmitter synthesis and metabolism.

• 01 Dopamine beta-hydroxylase converts dopamine to norepinephrine. This enzyme is absolutely vitamin C-dependent. Without adequate ascorbate, this conversion is impaired, which can produce elevated dopamine relative to norepinephrine, altering the stress response, attention, and arousal patterns.
• 02 Peptidylglycine alpha-amidating monooxygenase (PAM) activates neuropeptides including CRF, oxytocin, and substance P. These are directly involved in stress response regulation and mood. PAM requires ascorbate as an electron donor. Vitamin C deficiency impairs neuropeptide activation even when precursor levels are normal.
• 03 Histamine degradation benefits indirectly from vitamin C through stabilization of DAO (diamine oxidase) activity and mast cell membrane integrity. In clients with HNMT and COMT variants that slow histamine clearance, vitamin C reduces the histamine-driven neuroinflammation that directly worsens depressive symptoms.
• 04 Cortisol regulation is influenced by vitamin C in the adrenal cortex, which maintains the highest ascorbate concentrations of any tissue in the body. Adequate vitamin C reduces cortisol output in response to acute stress, buffering the HPA axis activation that drives so much of the fatigue and mood disruption in depression.
• 05 Neuroinflammation reduction occurs through vitamin C's ability to modulate NF-kB activity and reduce pro-inflammatory cytokine expression. In clients with IL-6, TNF, and IL-1B variants driving neuroimmune activation, this is a direct mechanism for reducing the inflammatory input driving depression.

Randomized controlled trials have shown that vitamin C supplementation reduces depression scores, with effects appearing within 2 to 4 weeks. Multiple studies have found that people with depression have significantly lower plasma and leukocyte ascorbate levels compared to matched controls, independent of dietary intake. This suggests increased utilization under oxidative and inflammatory stress, not simply inadequate intake.

For clients with SLC23A1 variants that impair vitamin C transport, dietary intake is insufficient to maintain adequate tissue levels. Consistent supplementation with ascorbic acid, not buffered or mineral-bound forms, produces the most reliable physiological effects. Doses between 2 and 6 grams daily, divided across the day, are standard in clinical orthomolecular practice.

Niacinamide and Depression: The Methyl Buffer No One Talks About

Niacinamide as a Methyl Buffer

This is the mechanism that makes niacinamide uniquely valuable for slow COMT carriers, and it is almost never discussed in conventional conversations about B3.

Niacinamide is methylated and excreted as N-methyl-nicotinamide. This process consumes SAMe (S-adenosylmethionine), the universal methyl donor. When methyl groups are being used to methylate and excrete niacinamide, they are not available to methylate catecholamines through COMT.

In slow COMT carriers with excess dopamine and norepinephrine, niacinamide acts as a methyl sink. It draws methyl groups away from catecholamine methylation, effectively slowing the COMT pathway further but in a controlled, predictable way that reduces the nervous system overstimulation driven by accumulated catecholamines. The result is a calmer, less reactive nervous system without any sedation or receptor downregulation.

• 01 NAD+ precursor activity is niacinamide's most studied role. NAD+ is required for mitochondrial energy production, DNA repair, and SIRT1 activity. In clients with UCP2, NDUFS7, and PPARGC1A variants compromising mitochondrial efficiency, niacinamide provides a direct substrate to support electron transport chain function and ATP generation in neural tissue.
• 02 PARP inhibition preserves NAD+ during periods of oxidative stress. When DNA sustains oxidative damage, PARP enzymes consume large amounts of NAD+ in the repair process. Niacinamide modulates this pathway, protecting the NAD+ pool and allowing mitochondrial function to remain stable under oxidative load, which is chronically elevated in depression-associated genotypes.
• 03 Tryptophan conservation is a consequential effect often overlooked. The body can synthesize niacinamide from tryptophan via the kynurenine pathway, consuming approximately 60mg of tryptophan per 1mg of niacin produced. When inflammation activates the kynurenine pathway, tryptophan is shunted away from serotonin synthesis and toward niacin production. Supplementing niacinamide directly reduces this demand on tryptophan, making more available for serotonin synthesis.
• 04 Glutamate modulation occurs through niacinamide's inhibition of the NMDA receptor at high doses. In clients with GRIN2B variants affecting NMDA receptor function, excessive glutamate signaling contributes to neural excitotoxicity and mood dysregulation. Niacinamide provides a gentle, non-pharmacological modulation of this pathway.
• 05 Antioxidant enzyme support comes through riboflavin (B2) sparing. Niacinamide's role in the glutathione recycling pathway through NADPH reduces the demand on riboflavin, allowing B2 to support FAD-dependent enzymes including MTHFR, supporting the methylation cycle where these clients are most compromised.

Dosing in Clinical Practice

In orthomolecular practice, niacinamide is dosed between 500mg and 1500mg daily, divided across two to three doses. The range is broader than most practitioners use because individual metabolic demand varies considerably based on genetic methylation throughput and oxidative stress load.

Starting low (25 to 50mg) and titrating upward allows observation of response. Clients with high oxidative stress and mitochondrial inefficiency often require and tolerate higher doses. Those with significant methylation impairment may need more time at lower doses as cofactor status stabilizes.

Why These Two Nutrients Work Together

Vitamin C and niacinamide address the same underlying problem from two complementary directions: reducing biochemical congestion and restoring the conditions under which the nervous system can regulate itself.

Vitamin C reduces the oxidative stress that activates neuroinflammation, supports neurotransmitter enzyme cofactors, recycles glutathione, and buffers HPA axis overactivation. Niacinamide provides the NAD+ substrate for mitochondrial function, buffers methyl group demand in slow COMT carriers, spares tryptophan for serotonin synthesis, and modulates NMDA receptor activity.

Together, they lower the background biochemical noise that makes the nervous system hypersensitive and unpredictable. They do not raise or suppress specific neurotransmitters. They restore the physiological conditions that allow the nervous system to regulate its own chemistry more effectively.

Magnesium belongs in this conversation as well. It is an essential cofactor for over 300 enzymatic reactions, including several in the methylation cycle and the mitochondrial electron transport chain. But vitamin C and niacinamide carry the most clinical weight for the specific genetic mechanisms driving depression in this population.